These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31022402)

  • 1. Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration.
    Lyons E; Donohue K; Lee JJ
    Gastroenterology; 2019 Aug; 157(2):275-277. PubMed ID: 31022402
    [No Abstract]   [Full Text] [Related]  

  • 2. "Assessment of Pressor Effects of Drugs"-A New US FDA Draft Guidance for Industry.
    Turner JR
    Ther Innov Regul Sci; 2018 Jul; 52(4):397-399. PubMed ID: 29996733
    [No Abstract]   [Full Text] [Related]  

  • 3. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift.
    Kearns GL; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61(6):740-743. PubMed ID: 33797778
    [No Abstract]   [Full Text] [Related]  

  • 4. Minors and a Dawning Paradigm Shift in "Pediatric" Drug Development.
    Rose K; Tanjinatus O; Grant-Kels JM; Ettienne EB; Striano P; Neubauer D
    J Clin Pharmacol; 2021 Jun; 61(6):736-739. PubMed ID: 33368372
    [No Abstract]   [Full Text] [Related]  

  • 5. US FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?
    Walovitch RC; Chokron P; Agarwal S
    Biomark Med; 2012 Dec; 6(6):839-47. PubMed ID: 23227850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
    Loomba R; Ratziu V; Harrison SA;
    Gastroenterology; 2022 Mar; 162(3):680-688. PubMed ID: 34822801
    [No Abstract]   [Full Text] [Related]  

  • 7. Eosinophilic Esophagitis: A Case Study of a 12-Year-Old Boy.
    Kiely K
    J Pediatr Health Care; 2017; 31(5):618-622. PubMed ID: 28396105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. End points in irritable bowel syndrome.
    Mangel AW; Fehnel SE
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract]   [Full Text] [Related]  

  • 10. Discussion: The FDA is Unprepared for Personalized Medicine.
    Tabarrok A
    Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
    [No Abstract]   [Full Text] [Related]  

  • 11. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
    Katzka DA; Loftus EV; Camilleri M
    Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic esophagitis: treatment with oral viscous budesonide.
    Zur E
    Int J Pharm Compd; 2012; 16(4):288-93. PubMed ID: 23050387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA insists on more women in drug trials.
    Josefson D
    BMJ; 1997 Oct; 315(7112):833. PubMed ID: 9353497
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of an FDA guidance document for clinical trials in SLE.
    Siegel JN
    Lupus; 1999; 8(8):581-5. PubMed ID: 10568893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA and IBS drug development.
    Mangel AW
    Am J Gastroenterol; 2009 Dec; 104(12):3106; author reply 3106. PubMed ID: 19956135
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological treatment of eosinophilic gastrointestinal disorders.
    Hua S; Cook D; Walker MM; Talley NJ
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1195-209. PubMed ID: 27191032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive enrichment designs for confirmatory trials.
    Lai TL; Lavori PW; Tsang KW
    Stat Med; 2019 Feb; 38(4):613-624. PubMed ID: 30277591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
    Weiskopf RB;
    Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.